Type 2 Diabetes Mellitus. From the start – combination therapy

Modern treatment of T2DM requires a shift in paradigm with appropriate intensification of therapy from the very first time of diabetes diagnosis. This is supported by data showing how even a moderate delay in achieving good glycemic control can translate into a later increased risk of developing dia...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Francesco Indovina, Pierpaolo Falcetta, Stefano Del Prato
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2018
Materias:	type 2 diabetes therapy early combination pathophysiology Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/fb619d96f96a42d595dec160bd095f64
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fb619d96f96a42d595dec160bd095f64
record_format	dspace
spelling	oai:doaj.org-article:fb619d96f96a42d595dec160bd095f642021-11-14T09:00:22ZType 2 Diabetes Mellitus. From the start – combination therapy2072-03512072-037810.14341/DM9867https://doaj.org/article/fb619d96f96a42d595dec160bd095f642018-11-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/9867https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Modern treatment of T2DM requires a shift in paradigm with appropriate intensification of therapy from the very first time of diabetes diagnosis. This is supported by data showing how even a moderate delay in achieving good glycemic control can translate into a later increased risk of developing diabetic complications. The recognition of the complexity of the pathogenesis of T2DM leads to the appreciation of the importance of attacking the disease from different angles, i.e. simultaneous tackling of multiple mechanisms contributing to hyperglycemia. From the turn of century a growing number of new anti-hyperglycemic agents have been made available. As compared to the older ones, these new medicines have a more targeted mechanism of action as they act at the level of the specific pathophysiologic disturbances accounting the development and progression of hyperglycemia. Because of that drugs can be use in combination taking advantage of their complementary mechanisms of action and synergistic. If introduced earlier in the natural history of the disease combination therapy may contribute avoiding undesirable exposure to even mild chronic hyperglycemia and provide early benefits. With respect to that in this review we will discuss advantages, disadvantages and still unanswered questions related to the use of early combination therapy in type 2 diabetes.Francesco IndovinaPierpaolo FalcettaStefano Del PratoEndocrinology Research Centrearticletype 2 diabetestherapyearly combinationpathophysiologyNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 21, Iss 5, Pp 386-394 (2018)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	type 2 diabetes therapy early combination pathophysiology Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	type 2 diabetes therapy early combination pathophysiology Nutritional diseases. Deficiency diseases RC620-627 Francesco Indovina Pierpaolo Falcetta Stefano Del Prato Type 2 Diabetes Mellitus. From the start – combination therapy
description	Modern treatment of T2DM requires a shift in paradigm with appropriate intensification of therapy from the very first time of diabetes diagnosis. This is supported by data showing how even a moderate delay in achieving good glycemic control can translate into a later increased risk of developing diabetic complications. The recognition of the complexity of the pathogenesis of T2DM leads to the appreciation of the importance of attacking the disease from different angles, i.e. simultaneous tackling of multiple mechanisms contributing to hyperglycemia. From the turn of century a growing number of new anti-hyperglycemic agents have been made available. As compared to the older ones, these new medicines have a more targeted mechanism of action as they act at the level of the specific pathophysiologic disturbances accounting the development and progression of hyperglycemia. Because of that drugs can be use in combination taking advantage of their complementary mechanisms of action and synergistic. If introduced earlier in the natural history of the disease combination therapy may contribute avoiding undesirable exposure to even mild chronic hyperglycemia and provide early benefits. With respect to that in this review we will discuss advantages, disadvantages and still unanswered questions related to the use of early combination therapy in type 2 diabetes.
format	article
author	Francesco Indovina Pierpaolo Falcetta Stefano Del Prato
author_facet	Francesco Indovina Pierpaolo Falcetta Stefano Del Prato
author_sort	Francesco Indovina
title	Type 2 Diabetes Mellitus. From the start – combination therapy
title_short	Type 2 Diabetes Mellitus. From the start – combination therapy
title_full	Type 2 Diabetes Mellitus. From the start – combination therapy
title_fullStr	Type 2 Diabetes Mellitus. From the start – combination therapy
title_full_unstemmed	Type 2 Diabetes Mellitus. From the start – combination therapy
title_sort	type 2 diabetes mellitus. from the start – combination therapy
publisher	Endocrinology Research Centre
publishDate	2018
url	https://doaj.org/article/fb619d96f96a42d595dec160bd095f64
work_keys_str_mv	AT francescoindovina type2diabetesmellitusfromthestartcombinationtherapy AT pierpaolofalcetta type2diabetesmellitusfromthestartcombinationtherapy AT stefanodelprato type2diabetesmellitusfromthestartcombinationtherapy
_version_	1718429503913459712

Type 2 Diabetes Mellitus. From the start – combination therapy

Ejemplares similares